Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

Anne‐Marie C. Dingemans, Lizza Hendriks, Thierry Berghmans, +35

Journal of Thoracic Oncology

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

L. Paz-Ares, E O’Brien, M. Mauer, +17

Annals of Oncology

MedicineClinical TrialsAdjuvant ChemotherapyImmune Checkpoint InhibitorPharmacotherapy +7

Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with <i>RAS–RAF</i> Mutations

Lisa Zimmer, Fabrice Barlési, Maria Martinez‐García, +16

Clinical Cancer Research

OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC

Fabrice Barlési, Clarisse Audigier-Valette, Enriqueta Felip, +21

Journal of Thoracic Oncology

Advanced NsclcEcog Ps 2Therapeutic EfficacyPharmacotherapyMedicine +2

Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) in NSCLC with brain metastases: Pooled analysis of KEYNOTE-021, 189, and 407

Steven Powell, Delvys Rodríguez‐Abreu, Corey J. Langer, +13

Annals of Oncology

Neuro-oncologyOncologyBrain MetastasesMedicineImmune Checkpoint Inhibitor +5

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

L. Paz-Ares, Fabrice Barlési, Salvatore Siena, +12

ESMO Open

Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC)

Guillem Argilés, José Saro, Neil H. Segal, +23

Annals of Oncology

Cancer ImmunosurveillanceSingle AgentMedicineImmunologyPathology +6

A phase I/IIA pharmacokinetic (PK) and serial skin and tumor pharmacodynamic (PD) study of the EGFR irreversible tyrosine kinase inhibitor EKB-569 in combination with 5-fluorouracil (5FU), leucovorin (LV) and irinotecan (CPT-11) (FOLFIRI regimen) in patients (pts) with advanced colorectal cancer (ACC)

E. Casado, Gunnar Folprecht, L. Paz-Ares, +7

Journal of Clinical Oncology

Tumor BiologyFolfiri RegimenOral Ekb-569MedicinePharmacology +13

Phase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC)

Neil H. Segal, José Saro, Ignacio Melero, +17

Annals of Oncology

Single AgentMedicineImmunologyColorectal CancerMetastatic Colorectal Cancer +5

OA09.01 First-line Nivolumab + Ipilimumab + Chemo in Patients With Advanced NSCLC and Brain Metastases: Results From CheckMate 9LA

David P. Carbone, Tudor–Eliade Ciuleanu, Manuel Cobo, +18

Journal of Thoracic Oncology

Advanced NsclcBrain MetastasesMedicinePharmacologyImmune Checkpoint Inhibitor +4